Contact
Please use this form to send email to PR contact of this press release:
Genmab Announces Submission of Supplemental Biologics License Application to FDA for Daratumumab in Front Line Multiple Myeloma
TO:
Please use this form to send email to PR contact of this press release:
Genmab Announces Submission of Supplemental Biologics License Application to FDA for Daratumumab in Front Line Multiple Myeloma
TO: